Press Releases

 
Press Releases
  Date Title View
Jan 26, 2005
South San Francisco, CA/ January 26, 2005 - Theravance, Inc. (NASDAQ: THRX) announced today that it has enrolled the first patient in a Phase 3 clinical study (Assessment of Telavancin for Treatment of MRSA Pneumonia - ATTAIN) of its investigational antibiotic, telavancin, in patients with hospital acquired pneumonia (HAP). ATTAIN is a multination...
Jan 10, 2005
SOUTH SAN FRANCISCO, Calif., January 10, 2005 -- Theravance, Inc. (Nasdaq: THRX) announced today that Rick E Winningham, Theravance's chief executive officer, is scheduled to present at the 23rd Annual JPMorgan Healthcare Conference on Monday, January 10, 2005 at 1:30 p.m. PT (4:30 p.m. ET). The conference will be held from January 10-13 at The Wes...
Jan 7, 2005
SOUTH SAN FRANCISCO, Calif., January 7, 2005 -- Theravance, Inc. (NASDAQ: THRX) announced today that Rick E Winningham, Theravance's chief executive officer, is scheduled to present at the 23rd Annual JP Morgan Healthcare Conference on Monday, January 10, 2005 at 1:30 p.m. PT (4:30 p.m. ET). The conference will be held from January 10-13 at ...
Jan 4, 2005
South San Francisco, CA, January 3, 2005 - Theravance, Inc. (NASDAQ: THRX) announced today that it has enrolled the first subjects in a Phase 1 clinical study designed to assess the safety, tolerability and pharmacokinetics of its investigational gastrointestinal (GI) prokinetic, TD-2749. TD-2749 is a selective 5-HT4 agonist discove...
Dec 7, 2004
South San Francisco, CA, December 7, 2004 - Theravance, Inc. (NASDAQ: THRX) today announced results from FAST 2, a Phase 2 clinical study with the investigational antibiotic telavancin (TD-6424). FAST 2 was a randomized, double blind, multinational study of intravenous telavancin dosed once a day or standard therapy (vancomycin dos...
Nov 3, 2004
Theravance, Inc. Reports Third Quarter 2004 Financial ResultsTheravance, Inc. Reports Third Quarter 2004 Financial Results Initiated Telavancin Phase 3 Clinical Studies Completed Initial Public Offering SOUTH SAN FRANCISCO, CA ...
Nov 2, 2004
Theravance Announces Results From Pre-clinical And Clinical Studies With Investigational Antibiotic Telavancin South San Francisco, CA, November 2, 2004 - Theravance, Inc. (NASDAQ: THRX) announced today that results from a Phase 2 clinical study with the investigational antibiotic telavancin (TD-6424) in patients with complicated ...
Oct 19, 2004
SOUTH SAN FRANCISCO, CA / October 19, 2004 - Theravance, Inc. (Nasdaq: THRX) announced today that it will release financial results for the period ended September 30, 2004 after market close on Wednesday, November 3, 2004 with an accompanying conference call at 5:00 p.m. EST. To participate in the live call by telephone, please dial 8...
May 11, 2004
SOUTH SAN FRANCISCO, CA / May 11, 2004 -- Theravance, Inc., a privately-held pharmaceutical company, announced today that the strategic alliance with GlaxoSmithKline (GSK), previously announced on March 31st, was consummated and funded after receiving the requisite regulatory and Theravance shareholder approvals. This innovative broad-based strateg...
May 11, 2004
South San Francisco, CA, May 11, 2004 - Theravance, Inc. announced today that results from a series of four in vitro and in vivo studies as well as human clinical studies with the investigational antibiotic telavancin (TD-6424) were presented at the 14th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Prague. ...
FirstPrevious
...
34
NextLast
= add release to Briefcase

Innoviva NASDAQ: INVA

$13.93 0.15 (1.09%) 09/25/17 12:38 PM ET Refresh Quote

Data provided by Nasdaq.
Minimum 15 minutes delayed.

Contact

Innoviva Investor Relations & Media
650.238.9640

For business development inquiries,
please contact bd@inva.com.